3/24
09:36 am
ovid
Ovid Therapeutics Inc. (NASDAQ: OVID) had its price target lowered by analysts at BTIG Research from $5.00 to $4.00. They now have a "buy" rating on the stock.
Low
Report
Ovid Therapeutics Inc. (NASDAQ: OVID) had its price target lowered by analysts at BTIG Research from $5.00 to $4.00. They now have a "buy" rating on the stock.
3/12
08:07 pm
ovid
Ovid Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
High
Report
Ovid Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
3/12
09:11 am
ovid
Ovid Therapeutics Inc. (NASDAQ: OVID) had its "outperform" rating re-affirmed by analysts at Wedbush.
Medium
Report
Ovid Therapeutics Inc. (NASDAQ: OVID) had its "outperform" rating re-affirmed by analysts at Wedbush.
3/11
08:00 am
ovid
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Low
Report
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
3/3
08:00 am
ovid
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
High
Report
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
2/27
08:00 am
ovid
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Low
Report
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
2/5
08:00 am
ovid
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Medium
Report
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
1/29
01:21 pm
ovid
Ovid Therapeutics Inc. (NASDAQ: OVID) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $4.00 price target on the stock.
Low
Report
Ovid Therapeutics Inc. (NASDAQ: OVID) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $4.00 price target on the stock.